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Summary
Blood transfusion can be life-saving. Anaesthetists regularly request and administer blood components to their
patients. All anaesthetists must be familiar with indications and appropriate use of blood and blood components and
their alternatives, but close liaison with haematology specialists and their local blood sciences laboratory is encour-
aged. Considerable changes in approaches to optimal use of blood components, together with the use of alternative
products, have become apparent over the past decade, leading to a need to update previous guidelines and adapt
them for the use of anaesthetists working throughout the hospital system.
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Recommendations
1 All patients should have their haemoglobin con-
centration (Hb) measured before listing for major
elective surgery.
2 Patients who are anaemic by the World Health
Organization deﬁnition (Hb men < 130 g.l1,
women < 120 g.l1) should be investigated before
elective surgery and treated appropriately, and
elective non-urgent surgery other than caesarean
section should be delayed.
3 Where blood transfusion is anticipated, this and
alternatives to transfusion should be discussed
with the patient before surgery, and this should be
documented.
4 Red blood cells should be transfused one unit at a
time, and the patient’s Hb should be checked
before each unit transfused, unless there is ongoing
bleeding or a large deﬁcit that needs correcting.
5 The use of intra-operative cell salvage and
tranexamic acid administration should be consid-
ered in all non-obstetric patients where blood
loss > 500 ml is possible and in traumatic and
obstetric major haemorrhage.
6 Blood components should be prescribed for small
children by volume rather than number of units.
7 Every institution should have a massive transfusion
protocol which is regularly audited and reviewed.
8 Group O red cells for transfusion should be read-
ily available in the clinical area, in case haemor-
rhage is life-threatening. Group-speciﬁc red cells
should be available within a very short time
(15–20 min) of the laboratory receiving correctly-
labelled samples and being informed of the emer-
gency requirement for blood.
9 During major haemorrhage due to trauma and
obstetrics, consideration should be given to trans-
fusing red cells and FFP in preference to other
intravenous ﬂuid.
10 Patients who continue to actively bleed should be
monitored by point-of-care and/or regular laboratory
tests for coagulation, ﬁbrinogen and platelet counts or
function, and a guide for transfusion should be FFP if
INR > 1.5, cryoprecipitate if ﬁbrinogen < 1.5 g.l1
and platelets if platelet count < 75 9 109.l1.
What other guidelines are available on
this topic?
A number of other guidelines are available, some of
which are quite recent, but none cover the breadth of
UK anaesthetic practice (Appendix 1).
Why was this guideline developed?
There is a need for a relevant up-to-date clinical guid-
ance for practising UK anaesthetists, critical care staff
and those from other specialities and backgrounds,
based on evidence where possible and with a focus on
safety.
How and why does this publication
differ from existing guidelines?
This is an updated guideline that also brings three pre-
vious AAGBI guidelines together (blood component
therapy, 2005; massive haemorrhage, 2010; and red cell
transfusion, 2008).
Introduction
Transfusion medicine is changing rapidly in response
to new developments. Considerable changes in
approaches to transfusion, together with the use of
alternative agents, have become apparent over the past
decade. Blood transfusion can be life-saving, but this is
a scarce and costly resource. There is increased focus
on appropriate transfusion practice to ensure quality
of service provision, and transfusion has been pro-
posed as a quality indicator in surgical care. Blood
transfusion usage remains high, particularly in trauma,
obstetrics, critical care and cardiovascular surgery.
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Anaesthetists are frequently involved in transfu-
sion decisions, the administration of blood and blood
components and as part of the team managing any
major haemorrhage. However, the use of allogeneic
blood components has serious implications and war-
rants careful consideration [1]. As a consequence,
there has recently been an expansion of interest in
safeguarding and checklists, blood conservation,
preservation techniques, coagulation proﬁling and the
use of haemostatic agents. Appropriate use of blood
components in patient care is of utmost importance.
Several recent major research publications that
have looked at transfusion practice were aimed at
patient safety, outcomes and individualised care,
including: use of restrictive transfusion protocols; adju-
vant therapies; substitution of blood components with
pooled factor concentrates; and use of point-of-care
(POC) testing to target speciﬁc component use (see
http://onlinelibrary.wiley.com/doi/10.1111/anae.2014.70.
issue-s1/issuetoc).
It is essential that our practice of blood transfusion
is safe and based on current, scientiﬁc, evidence-based
knowledge. A multidisciplinary approach that aims to
beneﬁt patients by the reduction in inappropriate
transfusions is paramount. This working party aims to
formalise guidance on the clinical indications and risks
of transfusion, blood conservation and the transfusion
process.
Patient blood management
Patient blood management is a patient-based approach
aimed at reducing the utilisation of blood transfusion
and improving the patient’s clinical outcome and
safety, and focuses on the optimisation of three factors
peri-operatively: patient, surgical and anaesthetic. It
has been recommended as a standard of care in the
UK National Health Service [2]. It focuses on three
‘pillars’ of care in surgical patients: detection and treat-
ment of peri-operative anaemia; reduction of peri-
operative blood loss; and harnessing and optimising
the patient-speciﬁc physiological reserve of anaemia
[3] (Table 1).
Anaemia
Pre-operative anaemia is common, occurring in up to
a third of patients before surgery, and associated with
worse outcomes. All patients should have their Hb
checked before listing for surgery. Patients who are
anaemic (Hb in men < 130 g.l1, women < 120 g.l1)
should be investigated and the cause treated appropri-
ately [4]. Patient pathways and pre-assessment clinics
should be established to allow timely and appropriate
management, and elective surgery should be delayed if
required [5].
Cell salvage
The use of cell salvage should be considered for high-
or medium-risk surgery in non-obstetric adult patients
where blood loss > 500 ml is likely, and in obstetric
major haemorrhage. In patients with malignancy or
obstetric haemorrhage, a leucocyte ﬁlter must be used.
Bacterial contamination of the surgical ﬁeld remains a
contra-indication. Cell salvage may also be continued
in the postoperative period [6].
Other aspects of patient blood management are
discussed throughout these guidelines.
Table 1 Patient blood management – measures that
should be taken in patients who are expected to bleed
during surgery.
Pre-operative
-Pre-operative Hb should be measured, recorded and
optimised as required
-Elective surgery should be postponed in patients with
untreated anaemia
-Review and consider stopping antiplatelet and anticoag-
ulant medication seven days before surgery
-Consider minimally invasive or laparoscopic surgical tech-
nique
-Point-of-care testing should be available with appropri-
ate training.
Intra-operative
-Position patient carefully to maintain venous drainage
-Use patient warming to maintain temperature > 36°
-Consider cell salvage if blood loss > 500 ml anticipated
-Consider giving tranexamic acid 1 g if blood loss
> 500 ml anticipated
-Apply restrictive transfusion threshold (Hb 70–80 g.l1
depending on patient characteristics and haemodynam-
ics)
-Consider use of topical haemostatic agents.
Postoperative
-Maintain oxygen delivery, targeting oxygen saturation
levels > 95%
-Single unit blood transfusion policy – re-assess Hb con-
centration and clinical need between units
-Postoperative drains or cell salvage.
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Process for transfusion
Administering the wrong blood type in error (with the
risk of ABO incompatibility) is the most serious out-
come of blood transfusion. Most of these incidents are
due to the failure of the ﬁnal identity checks carried
out between the patient (at the patient’s side) and the
blood to be transfused. All members of staff involved
in the administration of a blood component must be
trained and competency-assessed as per local policy.
Local policy will also stipulate if this is a one- or two-
person bedside check, with each person performing
the check independently [7]. Red cell transfusions
must be completed within 4 h of removal from the
blood fridge. All prescriptions for transfusion must be
documented in the patient record, either on the anaes-
thetic chart or on the drug/ﬂuid prescription chart.
Local policy for conﬁrmation of the transfusion must
be followed – it is a legal requirement that 100% of
blood components must be traceable [8]. Where blood
transfusion is anticipated, this should be discussed
with the patient before surgery and valid consent to
receive transfusion should be documented [9]. Patients
should be informed that they have received blood or
blood components before discharge from hospital as
they will otherwise be unaware; they should also be
informed that this removes them from the donor pool.
It is also important that the patient’s general practi-
tioner is informed.
The following guidance is for a manual checking
process at the bedside; the preferred system is an elec-
tronic transfusion management system.
-The patient must be positively identiﬁed. All patients
receiving blood components should be wearing an
identiﬁcation wristband containing four core identi-
ﬁers – ﬁrst name, last name, date of birth and patient
identiﬁcation number.
-Immediately before the transfusion, check the compo-
nent next to the patient, against the prescription.
-Check the four core identiﬁers on the compatibility
label attached to the blood component with the iden-
tiﬁcation attached to the patient. If there are any dis-
crepancies, do not proceed and call the transfusion
laboratory.
-Check that the compatibility label attached to the
blood component has the same blood group and
14-digit component donation number (or batch
number for coagulation factors) as the sticker on
the blood component.
-Visually check the blood component for any leakage,
discolouration or presence of any clots or clumps.
-Check the expiry date and time.
Transfusing an unidentiﬁed patient
All hospitals should have a clear local policy for trans-
fusion of patients whose identity is unknown. In emer-
gency situations or where the patient cannot
immediately be identiﬁed, the patient should still have
identiﬁcation attached stating unknown male or female
and a unique identiﬁcation number. The blood sample
sent to the transfusion laboratory should contain these
exact details.
In the event that the patient’s identity becomes
known, new identiﬁcation must be attached to the
patient and a new transfusion sample collected and
fully labelled with the known patient’s details.
Monitoring for adverse events or reactions
during transfusions
Clinical observations should include heart rate, blood
pressure, temperature and respiratory rate, as per local
guidelines (national guidelines deﬁne a minimum of
pre-transfusion, at the end of transfusion and 15 min
after transfusion). If there are any signs of a transfu-
sion reaction, such as tachycardia, rash, breathlessness,
hypotension or fever, stop the transfusion and contact
the laboratory immediately [10]. Management may
include the administration of antihistamine or steroid
drugs, or intramuscular/intravenous adrenaline if life-
threatening [11]. Diagnosis of a transfusion reaction
during ongoing haemorrhage may be difﬁcult, but if
concern arises, the documentation should be double-
checked for administration errors and further analyses
performed as per local protocols.
Transferring blood with a patient
Blood components should be transferred with patients
at high risk of requiring transfusion en route or imme-
diately on arrival. There should be effective communi-
cation between the blood transfusion laboratories
involved, according to regional policy. Blood compo-
nents must be transported in a storage box suitable to
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maintain their integrity, along with accompanying
paperwork, and careful handover is required. When
the patient arrives at their destination, the receiving
transfusion laboratory should be immediately informed
that blood was transported. The patient should be
issued with a new identity wristband, a new sample
taken for cross-match and more blood issued; until
this is available, blood transferred with the patient
may be administered if required.
Red blood cell transfusion
Red blood cell (RBC) transfusion is potentially life-saving
for the treatment of blood loss (Major haemorrhage –
see next section). In patients who do not have active
bleeding and in normovolaemic patients, the Hb should
be measured before and after every unit of RBC
transfused. Near-patient measurement of Hb may be
particularly useful, but laboratory measurement remains
the gold standard. Haemoglobin concentration is depen-
dent on both red cell mass and plasma volume; it may
fall due to haemodilution due to intravenous ﬂuid
administration. In the bleeding patient, haemoglobin
concentration may remain falsely elevated despite sig-
niﬁcant blood loss due to inadequate ﬂuid resuscitation.
Other potential indications for RBC transfusion
are clinical signs and biochemical markers of
inadequate oxygen delivery, such as elevated blood
lactate concentration, a low Ph and low central or
mixed venous oxygen saturation.
Optimum haemoglobin transfusion trigger
Recent publications comparing more liberal transfusion
strategies (typical transfusion trigger Hb 90–100 g.l1)
with more restrictive strategies (typical transfusion
trigger Hb 70–80 g.l1) did not show any difference in
patient outcomes [12, 13]. Therefore, a general Hb
threshold of 70 g.l1 should apply as a guide for red
cell transfusion. Uncertainty remains for patients with
ischaemic heart disease, including acute coronary syn-
drome and after cardiac surgery [14], and higher
thresholds (80 g.l1) may be more appropriate in such
circumstances.
Major haemorrhage
Major haemorrhage is variously deﬁned as loss of
more than one blood volume within 24 h (around
70 ml.kg1, > 5 l in a 70 kg adult); 50% of total blood
volume lost in < 3 h; or bleeding in excess of
150 ml.min1. A pragmatic clinically-based deﬁnition
is bleeding which leads to a systolic blood pressure of
less than 90 mm Hg or a heart rate of more than
110 beats.min1. Major haemorrhage is a signiﬁcant
cause of mortality and morbidity in the peri-operative
setting. Appropriate and effective management inte-
grates multiple factors, including: recognition; commu-
nication; timely delivery of blood products; and
application of deﬁnitive modalities of treatment (sur-
gery and interventional radiology) [15].
Major haemorrhage protocol
Policies should be deﬁned in an institutional major
haemorrhage protocol. Activation of a protocol should
result in the immediate release and administration of
blood components for initial resuscitation, without
prior approval from a haematologist. Such protocols
perform best when speciﬁc to clinical areas such as the
emergency department or the labour ward, and are
designed to include robust and clearly understood acti-
vation and communication from bedside to laboratory.
Their activation should also mobilise other resources,
such as additional (senior) staff including portering,
blood warmers, pressure infusers and cell salvage
devices [16].
A clear mechanism for the escalation of a team
response and for identifying individuals with sufﬁcient
seniority and experience to undertake the key roles of
team leader (senior anaesthetist) and co-ordinator is
essential to the process, as is enabling a single point of
contact with the laboratory and other support services.
Initial resuscitation
Most major haemorrhage packs will contain four units
of RBCs and four units of FFP (equivalent to 15–
20 ml.kg1 in a standard adult); platelet concentrate
may also be provided. Administration should be via
wide-bore intravenous access, or intra-osseous access
until the former can be obtained.
Group O red cells should be readily available and
transfused if haemorrhage is life-threatening. It is
essential to give group O Rh-negative red cells to chil-
dren and women of childbearing potential, but group
O Rh-positive red cells may be used in adult men.
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Group-speciﬁc red cells should be rapidly made
available (within 15–20 min) by the laboratory after
receiving a correctly labelled blood group sample and
being informed of the emergency requirement for
blood. Emergency Group O red cells should continue
to be provided where timely and safe issue of group-
speciﬁc red cells is not possible.
Haemostatic resuscitation
This describes the process of restoring and sustaining
normal tissue perfusion with the emphasis on preser-
vation of effective clotting. Coagulopathy is associated
with haemorrhage (consumption) and transfusion of
blood products (dilution), as well as mechanism of
injury in trauma; this may exacerbate the haemorrhage
and resultant morbidity. Point-of-care or laboratory
testing should be used to guide management.
During resuscitation, the following should be pre-
vented/treated: hypothermia; acidosis; hypocalcaemia
(aim for ionised calcium > 1.0 mmol.l1); and hyper-
kalaemia.
Special situations
Critical care
Anaemia is prevalent during critical illness. In addition
to blood loss and sampling, haemodilution and
impaired erythropoiesis may be important contributors
[17]. Patients with anaemia demonstrate biochemical
abnormalities similar to those with chronic inﬂamma-
tory diseases.
Although biochemical markers of tissue hypoxia,
notably blood lactate concentration, are frequently
elevated, evidence does not support increasing
oxygen delivery with RBC transfusion when the Hb
is > 70 g.l1, unless the patient has cardiac disease
[18].
One important group of patients admitted to ICU
are patients with haematological malignancies. Overall,
patients with cancer form one of the larger groups of
recipients of blood components. However, unlike other
patient groups, the anaemia in patients with haemato-
logical malignancies reﬂects an underlying bone marrow
failure, and therefore, it is unclear to what extent ﬁnd-
ings from the majority of randomised trials conducted
in surgery or general critical care can be extrapolated to
cancer, although the same broad principles of restrictive
use of red cells commonly apply (70–80 g.l1 for red
cell transfusion).
Obstetrics
Estimating blood loss at delivery is notoriously difﬁ-
cult, and every effort should be made to directly mea-
sure abnormal bleeding across all settings in the
delivery suite [19]. Early recognition of bleeding by
changing bed linen and pads immediately after deliv-
ery and systematically weighing new blood-soaked
pads correlates with the fall in Hb concentration and
improves outcome.
As soon as abnormal bleeding is recognised,
> 500 ml after a vaginal delivery and > 1000 ml after
a caesarean delivery, the obstetrician, anaesthetist and
senior midwife should attend the mother. Blood
should be taken for full blood count (Hb), clotting
studies, group and screen, and a venous blood gas for
rapid Hb measurement and lactate (> 2 mmol.l1 is
an indicator of shock). Cell salvage is recommended if
abnormal bleeding occurs during caesarean section,
and a leucocyte ﬁlter should be used for autotransfu-
sion of processed blood.
Severe early consumptive coagulopathy is associ-
ated with abruption, amniotic ﬂuid embolus and severe
bleeding with pre-eclampsia. Early use of FFP before
RBC may be required.
Postpartum haemorrhage associated with atony or
trauma is unlikely to be associated with haemostatic
impairment unless the diagnosis is delayed. Protocol-
led use of blood products will lead to overtransfusion
of FFP in the majority of cases [20]. If coagulation
tests are not known, then FFP should be withheld until
four units of RBC have been given. If no coagulation
results are available and bleeding is ongoing, then,
after four units of RBC, four units of FFP should be
infused and 1:1 ratio of RBC–FFP transfusion main-
tained until the results of haemostatic tests are known.
Point-of-care (POC) testing is recommended in this
setting [21].
Hypoﬁbrinogenaemia, below normal levels for preg-
nancy, predicts the risks of ongoing postpartum haem-
orrhage. The normal plasma ﬁbrinogen concentration in
pregnancy is 4–6 g.l1, and a laboratory Clauss ﬁbrino-
gen of < 3 and especially < 2 g.l1, with ongoing bleed-
ing, is associated with progression to major obstetric
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bleeding [22]. Fibrinogen replacement with cryoprecipi-
tate or ﬁbrinogen concentrate should be considered in
these circumstances, if there is bleeding.
Monitoring of haemostatic function in obstetric
haemorrhage is particularly important; laboratory
testing is often too slow during obstetric haemor-
rhage, and therefore, POC testing is preferred. Tests
should include plasma ﬁbrinogen concentration or
POC equivalent [21]. With ongoing bleeding, any
abnormalities should be treated, as this indicates sig-
niﬁcant haemostatic impairment in the obstetric
patient. Platelet transfusions are rarely required and
should only be given once the platelet count is
known.
Tranexamic acid reduces total blood loss and
should be given if postpartum haemorrhage is severe
(> 500 ml after a vaginal delivery and > 1000 ml after
a caesarean delivery), at an initial dose of 1 g.
Paediatrics
There is little direct evidence to guide the use of blood
products in children, and generally the guidance
intended for adults can be safely applied to children
with some modiﬁcations (speciﬁcally in transfusion
volumes). ‘Restrictive’ approaches to transfusion are
appropriate for almost all children older than
3 months of age. Higher transfusion thresholds are
often applied to neonates and children with congenital
heart disease. Although thresholds are not clearly
deﬁned, there is evidence that quantities of transfusion
can be reduced in these patients by applying moder-
ately restrictive thresholds for transfusion without
adverse effect on outcome [23, 24]. Neonates should
receive components speciﬁed for neonatal use, includ-
ing cytomegalovirus-negative blood products.
The volume of blood to be administered requires
modiﬁcation depending on the size of the patient. It is
recommended that blood in children should be pre-
scribed in volume rather than number of units. In
practice, sensible rounding to the nearest unit will be
more efﬁcient.
• A transfusion of 10 ml.kg1 of RBC should increase
Hb by approximately 20 g.l1.
• Cryoprecipitate should be given in a dose of 5–
10 ml.kg1.
• Platelets should be given in a dose of 10–
20 ml.kg1.
• Fresh frozen plasma may be given in doses of 10–
15 ml.kg1.
Tranexamic acid can be used in children: a loading
dose of 15 mg.kg1 followed by infusion 2 mg.kg1.h1
should be used in trauma [25].
With technical reﬁnements, cell salvage can be
useful in children, even if the absolute volume of blood
loss is less than 500 ml [26].
Major haemorrhage is rare in children outside of
highly specialist areas of practice. The guidance sug-
gested for adults can be generally applied, though
requires an awareness of the size of the child and the
clinical context of the bleeding. Blood volume of a
child is estimated at 70 ml.kg1 but may be as high as
100 ml.kg1 in newborns. Devices for vascular access
and rapid administration of blood should be appropri-
ate for the size of the child and rate of blood loss.
Children are at particular risk of electrolyte imbalance
and hypothermia during rapid administration of blood
products.
Trauma
During active bleeding, follow the principles of damage
control resuscitation:
Early haemorrhage control
Ensure clinical treatment is constantly directed towards
haemorrhage control. Use temporary haemostatic
devices (pressure, tourniquets, etc.) followed as soon as
practically possible by surgery or interventional radio-
logical control of haemorrhage.
Permissive hypotension
Do not try to normalise blood pressure during active
haemorrhage. Maintain a minimum acceptable preload
and blood pressure with volume resuscitation alone;
this may need to be modiﬁed in the presence of
trauma in head and spinal injuries. The use of vaso-
pressors should be avoided during active haemorrhage.
Avoid crystalloid and colloid administration
During uncontrolled haemorrhage, avoid clear ﬂuids
for volume resuscitation unless there is profound
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hypotension and no imminent availability of blood
products.
Target trauma-induced coagulopathy
Deliver blood products empirically at ﬁrst, and use lab-
oratory or point-of-care tests of coagulation to guide
therapy as soon as available [27].
Give tranexamic acid 1 g immediately, but avoid if
more than 3 h after injury, unless there is ongoing
evidence of hyperﬁbrinolysis (as suggested by POC
testing).
Whilst haemorrhage is being controlled, adminis-
tration of RBC and FFP in a ratio of 1:1 should be
used to replace ﬂuid volume [28]. Consider the admin-
istration of cryoprecipitate (two pools) and platelets
(one adult therapeutic dose) until test results are avail-
able and bleeding is controlled. Once control is
achieved, blood components should be administered as
guided by testing at the earliest opportunity (see Moni-
toring section, blood components).
Cardiac surgery
Anaemic patients have an increased risk of mortality
and complications following cardiac surgery [29]. Elec-
tive cardiac surgery should not be undertaken in an
anaemic patient without prior investigation and treat-
ment as considered necessary.
Viscoelastic testing is recommended to guide
transfusion [30]. The use of local transfusion protocols
guided by point-of-care testing may lead to appropri-
ate transfusion with reduced costs. The evidence base
for the efﬁcacy of fresh frozen plasma is minimal and
of poor quality [31].
The effect of cardiopulmonary bypass on platelet
function may make the use of a higher platelet count
(> 75 9 10-9.l1) necessary after bypass.
There is no clear evidence of the beneﬁt of platelet
function analysis except in those patients who have
taken PY12 receptor inhibitors such as clopidogrel
within 5 days of surgery [32].
Monitoring
Laboratory testing
Traditional tests such as APTT and PT/INR have been
standardised for the monitoring of anticoagulants and
are designed to diagnose and manage factor deﬁcien-
cies such as haemophilia. Standardisation within labo-
ratories has made the results very reliable.
The PT and APTT were not designed to monitor
coagulation deﬁciencies during haemorrhage and sug-
gested INR and APTT ratios or triggers, which are
widely quoted to guide coagulation product replace-
ment, are based on small historic studies that have lit-
tle relevance today. Slow turnaround time also means
that the results do not reﬂect the dynamic clinical situ-
ation during ongoing haemorrhage [33].
Point-of-care testing
Point-of-care testing has a shorter turnaround time
and represents a more global and therefore more rel-
evant reﬂection of coagulation status [34]. Point-of-
care testing is increasingly popular for general and
cardiac surgery, trauma units, intensive care and
obstetrics. Point-of-care testing for Hb concentration
is commonly used, such as blood gas analysis or the
HemoCue (€Angelholm, Sweden), which both corre-
late well with laboratory measurements [35]. The
activated clotting time (ACT) is also well validated
and should be used routinely whenever heparin is
administered, particularly in cardiac and vascular
surgery.
Targeted blood component therapy based on POC
testing has been shown to be safe and effective, and to
decrease blood product usage. However, there are cur-
rently no studies that show improved patient outcome
compared with standard treatment [32].
At the current time, there are two commercially
available semi-automated viscoelastic machines that
use similar technology: thromboelastometry (ROTEM,
TEM International, Munich, Germany) and thromboe-
lastography (TEG, Haemonetics Corp, Braintree, MA,
USA). One manufacturer cannot be recommended
above the other.
There are no universal algorithms across the spe-
cialities, and local protocols are required based on
institutional procedures. There is limited interchange-
ability between TEG and ROTEM, and development
and validation of separate treatment algorithms for the
two devices are required [36].
There are concerns about standardisation of both
assays with poor quality control and assurance and a
wide variation in results between centres [37]. It is
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good practice to pair coagulation samples and send a
second sample for laboratory-based analysis.
Drugs
An increasing number of patients take either anticoagu-
lants or antiplatelet agents. All patients require careful
pre-operative medication optimisation before surgery.
The management of drugs related to antithrombotic
therapy in the peri-operative setting is a common prob-
lem, balancing bleeding risk with thrombosis.
Patients at high risk (> 10% risk of thrombotic
events per year) of thrombosis should be considered
for bridging anticoagulation, or in the following
circumstances:
-venous thromboembolic event within the last
3 months, or
-prosthetic (mechanical) heart valve
Bridging anticoagulation usually consists of low
molecular weight heparin. The dose and type of the low
molecular weight heparin depends on the patient’s weight,
timing of surgery, type of procedure and thrombotic risks.
Warfarin (Vitamin K antagonist)
The international normalised ratio (INR) is used to
monitor the effectiveness of warfarin. In most situa-
tions, INR is maintained between 2.0 and 2.5.
The peri-operative management of warfarin is
summarised in Table 2. In patients with atrial ﬁbrilla-
tion on warfarin, routine use of bridging anticoagula-
tion with low molecular weight heparin before surgery
is not recommended.
For emergency reversal of warfarin, prothrombin
complex concentrate (PCC) 50 IU.kg1 is recom-
mended. Intravenous vitamin K (10 mg) may also be
given, but this may preclude re-warfarinisation for a
number of days. Fresh frozen plasma is an alterna-
tive if PCC is not available [37], but should not be
used as elective prophylaxis in patients taking
warfarin.
Novel oral anticoagulants
Novel oral anticoagulants have more predictable phar-
macodynamics and a faster onset of action with a
shorter half-life than warfarin. There are currently
three drugs on the market; these are increasingly used
for management of patients with atrial ﬁbrillation;
after stroke and transient ischaemic attacks; and pro-
phylaxis/management of venous thromboembolism
[38].
Their half-life varies, especially in the presence of
renal impairment. Currently, there are no speciﬁc rou-
tine coagulation tests to determine their effectiveness.
Regarding antidotes, the United States Food and Drug
Administration and the European Commission have
recently approved the ﬁrst of these, idarucizumab
(Praxbind, Boehringer Ingelheim International, Ingel-
heim am Rhein, Germany), for the emergency reversal
of dabigatran; other antidotes are currently undergoing
clinical trials.
Dabigatran is a direct thrombin inhibitor. Half-life
depends on extent of renal impairment (normally 48–
72 h). For major elective surgery, neuraxial blockade
and in patients with renal dysfunction, the drug should
be stopped 5 days before surgery. For others, it can be
stopped 3 days before surgery.
Rivaroxaban and apixaban are direct factor Xa
inhibitors. Half-life is 5–13 h and is less dependent on
renal function. For major elective surgery, neuraxial
blockade and in patients with renal dysfunction, the
Table 2 Peri-operative optimisation of warfarin anticoagulation for major surgery. Bridging with LMWH required
for high-risk patients, patients who suffered recent thromboembolic events or patients with mechanical prosthetic
heart valves.
Day 5 Days 4, 3, 2 Day 1 Surgery Postoperative
Last dose
of warfarin.
Treatment dose
LMWH
(consider Vitamin
K if INR > 2.5
Half treatment
dose LMWH
Omit LMWH.
Check INR
Prophylactic LMWH
until warfarin is
commenced.
INR, international normalised ratio; LMWH, low molecular weight heparin.
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drug should be stopped 3 days before surgery, other-
wise stop 24–48 h before surgery.
If surgery is urgent, consider PCC 50 IU.kg1,
correct other abnormal coagulation tests and check
platelets. Bridging anticoagulation is not required
except in patients with recent (< 3 months) history of
pulmonary embolism or deep venous thrombosis.
Antiplatelet drugs
These drugs cause irreversible inhibition of platelets;
replenishment of platelets occurs at a rate of 10–15%
per day. The restoration of normal platelet function
depends on the individual drug and dosage.
Aspirin inhibits the production of thromboxane. It
should be continued for most procedures until the day
before surgery. In patients at low risk of cardiovascular
events having major surgery and those undergoing
high-risk procedures such as intracranial surgery,
aspirin should be discontinued 5 days before the pro-
cedure.
Clopidogrel is an oral, thienopyridine-class antipla-
telet agent, and the active metabolites circulate for up
to 18 h after the last dose. Clopidogrel should be
stopped 7 days before surgery unless point-of-care
testing is used to check platelet function.
The drugs prasugrel and ticlopidine are also
thienopyridine-class antiplatelet drugs similar to clopi-
dogrel. The same recommendations as for clopidogrel
apply to the above drugs.
Antiplatelet drugs and non-cardiac surgery in
patients with coronary stents
The management of these drugs in patients with coro-
nary stents in situ depends on the type of stent, time
after the coronary event and surgery type (major vs
minor). Communication with the cardiology team is
key. Elective surgery should be postponed for at least
4–6 weeks after bare metal stent implantation and
6 months after drug-eluting stent implantation.
Aspirin may be continued during the peri-operative
period except in closed space surgery such as intracra-
nial and spinal surgery.
For emergency surgery, management depends on
the antiplatelet agent and when the last dose was
taken. Platelet transfusion should be reserved as an
additional measure for critical bleeding.
Drugs that decrease blood loss
Tranexamic acid is a synthetic derivative of the amino
acid lysine that inhibits plasminogen activation, thus
preventing impairment of ﬁbrinolysis. In the last few
years, there is increased evidence that its use may
reduce bleeding in trauma, cardiac surgery and other
major surgery. Seizures have been reported when high
doses are given, but there is little evidence of other
side effects [39]. Dose is variable, but 1 g bolus is rec-
ommended, and an additional infusion of 500 mg.h1
may also be considered [40].
Aprotinin is a serine protease inhibitor antiﬁbri-
nolytic which acts by inactivating free plasmin. The
drug was withdrawn from the market in 2007 due to
safety issues with increased incidence of renal impair-
ment and anaphylactic reactions. Recently, regulators
have licensed the drug only for myocardial revasculari-
sation (coronary artery bypass surgery) [41].
Blood components
Before administration of any blood component, the
patient’s details should be checked against those on
the bag (see red blood cell transfusion section). Blood
components have speciﬁc storage and expiry times.
Every effort must be made to avoid wastage.
In haematological malignancy, the clinical team
must be consulted before administering blood compo-
nents because of the need for speciﬁc requirements. The
transfusion threshold may be different to non-haemato-
logical patients. A small number of patients require
transfusion with irradiated blood components to pre-
vent them developing transfusion-associated graft-
versus-host disease (TA-GVHD), which is rare, but
usually fatal. Patients with the following conditions require
irradiated blood: congenital immunodeﬁciency states, for
example Di-George’s syndrome; allogeneic bone marrow
transplant recipients and donors; autologous bone mar-
row-transplanted patients; Hodgkin’s lymphoma; purine
analogue therapy including new agents clofarabine and
bendamustine; and patients who receive antithymocyte
globulin (anti-CD52) therapy (alemtuzumab) [42].
Fresh frozen plasma
Fresh frozen plasma is leucodepleted plasma rapidly
frozen to below 25 °C to maintain the integrity of
labile coagulation factors. The use of FFP has
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increased signiﬁcantly in the past few years [38]. Given
that anti-HNA and anti-HLA antibodies occur at higher
frequency in multiparous women, implementation of
male-only plasma in component therapy began in the
UK in 2003, and this has reduced the incidence of trans-
fusion-related acute lung injury (TRALI) [43].
Fresh frozen plasma can be thawed using a dry
oven (10 min), microwave (2–3 min) or in a water
bath (20 min). Thawed FFP can be used for up to
24 h as long as it is stored at 4 °C. This time has
recently been extended to 5 days when stored at 4 °C
for use in major haemorrhage associated with trauma.
Once out of the fridge, it must be used within 30 min,
and once thawed, it should never be refrozen. Approx-
imate volume per bag is 300 ml.
Fresh frozen plasma contains all the factors of the
soluble coagulation system, including the labile factors
V and VIII to a varying degree. The ﬁbrinogen content
of four units of FFP is approximately 2 g, compared
with approximately 4 g ﬁbrinogen in two pools of
cryoprecipitate.
Fresh frozen plasma should be the same group as
the patient. If the blood group is unknown, group AB
FFP is preferred, as it does not contain any anti-A or
anti-B. If group O FFP is given to non-group O chil-
dren, it should be high-titre (HT) negative. The rec-
ommended therapeutic dose is 15 ml.kg1.
To reduce the risk of variant Creutzfeldt–Jakob
disease, FFP for use in all those born in 1996 or later
is sourced outside of the UK and has undergone viral
inactivation (either with methylene blue or solvent
detergent treatment).
Indications for FFP use include the following:
• replacement of coagulation factors during major
haemorrhage, particularly trauma and obstetrics;
• acute disseminated intravascular coagulation (DIC)
with bleeding;
• in patients who are actively bleeding and whose
INR is > 1.5 (or POC equivalent);
• immediate reversal of warfarin-induced haemorrhage
when PCC is not available (PCC is the ﬁrst choice);
• thrombocytopenic purpura usually with plasma-
pheresis preferably using pathogen-inactivated FFP;
and
• replacement of coagulation factors when speciﬁc
factors are not available (uncommon).
There is a very limited role for FFP in the man-
agement of (mild–moderate) coagulation abnormalities
frequently seen in many non-bleeding critically ill
patients before invasive procedures. Fresh frozen
plasma is not recommended for routine use in patients
with cirrhosis/liver disease unless signiﬁcant coagu-
lopathy is identiﬁed, as again current understanding
indicates that isolated abnormalities of the PT or
APPT do not reﬂect a ‘balanced haemostasis’. Fresh
frozen plasma should not be used simply as routine
circulatory volume replacement.
Cryoprecipitate
Cryoprecipitate is also a leucodepleted plasma product
containing concentrated factor VIII, von Willebrand
factor, ﬁbrinogen, factor XIII and ﬁbronectin, pro-
duced by further processing of FFP. It is stored
at25 °C; once thawed for administration, it can be
kept at ambient temperature for 4 h, and should not
be kept in the fridge again [42].
In the UK, it is mainly available as pooled bags of
ﬁve units, 100–200 ml per bag. It is also available as
one unit of 20–40 ml. Each single unit has 400–
450 mg of ﬁbrinogen, and pools of ﬁve units contain
at least 2 g.
The adult dose is two pools; transfuse using a
standard blood giving set with a 170- to 200-lm
ﬁlter.
Indications for cryoprecipitate include the following:
• hypoﬁbrinogenaemia due to major haemorrhage
and massive transfusion. There is increased use of
cryoprecipitate in major trauma, obstetric haem-
orrhage and cardiac surgical bleeding. During
major haemorrhage, ﬁbrinogen should be main-
tained > 1.5 g.l1, except in active obstetric haem-
orrhage where ﬁbrinogen should be maintained
> 2 g.l1;
• combined liver and renal failure with bleeding;
• bleeding associated with thrombolytic therapy;
• disseminated intravascular coagulation with ﬁbrino-
gen < 1.0 g.l1; and
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• advanced liver disease, to maintain ﬁbrinogen level
> 1.0 g.l1.
Cryoprecipitate for use in all those born in 1996
or later is made from FFP sourced outside of the UK
and has undergone viral inactivation with methylene
blue. These components are available as single units
for smaller children and pooled units for older chil-
dren and young adults.
Platelets
Platelets are either made from pooled buffy coat-
derived platelets from four whole blood donations, sus-
pended in platelet additive solution and the plasma of
one of the four donors (who is male), or as an adult
therapeutic dose obtained from a single donor by
apheresis donation. Both can be used interchangeably;
NHSBT recommends that recipients born on or after
1st January 1996 should receive apheresis donation
platelets where possible.
There is increased use of platelets in the last few
years. The greatest demand is for haemato-oncology
patients; platelets should not be administered to
patients with chemotherapy-induced thrombocytopenia
in the absence of bleeding, unless their platelet count
is < 10 9 109.l1.
The risk of transmission of bacterial infection (1
in 12,000) is higher than other blood components
because platelets are stored at 22 °C. This risk is
reduced by bacterial screening before release.
Platelets do not have to be the same group as the
patient, but where group O platelets are given to a non-
group O child they should be selected to be high-titre
negative. D-negative children and women of childbear-
ing potential should receive D-negative platelets because
of the small risk of developing immune anti-D.
Platelet concentrate should be stored at 22 °C with
constant gentle agitation in an approved incubator.
Platelets must not be placed in a refrigerator. Transfu-
sion should ideally be commenced within 30 min of
removal from the platelet storage incubator. Each pack
contains 250–350 ml; platelet count in the pack is
> 2.4 9 1010.l1 per adult dose, and transfusion
should lead to an increase in the patient’s platelet
count by approximately 30 9 109.l1. The patient’s
platelet count should be repeated after transfusion.
A standard adult therapeutic dose should be infused
over a period of 30 min through a standard blood
administration set or platelet administration set incor-
porating a 170- to 200-lm ﬁlter. Do not give through a
set that has already been used for red cells. No drugs
should be added directly to the unit of platelets.
Indications for platelets include the following:
• prevention and treatment of bleeding due to
thrombocytopenia or platelet function defects.
• If patient is actively bleeding, transfuse to a platelet
count > 75 9 109.l1
If not bleeding, the following triggers should be
applied:
• routine prophylactic use: 10 9 109.l1;
• prophylactic use with additional risk factors (e.g.
Sepsis): 10 – 20 9 109.l1;
• other major surgery or invasive procedures:
50 9 109.l1;
• neuraxial blockade: 50 9 109.l1; and
• prophylactic use in closed compartment surgery
(eye, brain): 100 9 109.l1.
In the UK, the availability of platelets is centralised
and will depend on the demand and distance from
nearest blood centre. Clinicians need to be aware of
local laboratory arrangements and normal time inter-
val for obtaining platelets from central storage.
Special blood components
Prothrombin complex concentrate
Prothrombin complex concentrate (in the UK) comes
as four-factor concentrate containing factors II, VII, IX
and X, with protein S, C and heparin. It can be rapidly
reconstituted providing a high concentration of these
four clotting factors in a small volume. It is indicated
in acquired factor deﬁciency and for urgent reversal of
warfarin. There is limited evidence for use in any other
setting.
Fibrinogen concentrate
There has been considerable interest in ﬁbrinogen con-
centrate. It is widely used in mainland Europe in the
management of bleeding following surgery or trauma.
Recent trials in cardiac surgery have not shown any
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beneﬁt from its use. It is only licensed for use in
congenital hypoﬁbrinogenaemia in the UK.
Recombinant factor viia
Licensed for use in haemophiliacs with inhibitors. It is
the most potent thrombin generator available at pre-
sent. Late use in the exsanguinating patient is almost
always associated with no beneﬁt, a high risk of mor-
tality and thrombotic complications. Following cardiac
surgery, it has been shown to reduce re-operation rates
and transfusion in the bleeding patient. However, its
use may increase the risk of thrombotic complications
and its use except under haematological direction
cannot be recommended [44].
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